Covidien’s pharma business buys CNS Therapeutics for $100 million
Mallinckrodt, the soon-to-be spun-out pharma business of Covidien, is buying a Minnesota company that is developing drugs to treat neurological disorders and severe chronic pain by delivering them to specific locations in the central nervous system. The Hazelwood, Missouri unit of Covidien announced Monday that it is acquiring CNS Therapeutics’ outstanding capital stock for $100 […]